High-Expression of Cytoplasmic Poly (A) Binding Protein 1 (PABPC1) as a Prognostic Biomarker for Early-Stage Esophageal Squamous Cell Carcinoma

Pu, Jiangtao; Zhang, Tao; Zhang, Dengguo; He, Kaiming; Chen, Yonghong; Sun, Xingwang; Long, Wenbo

doi:10.2147/cmar.s317631

Cited by 8 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of PABPC1 was localized inside the cytoplasm of tumor cells. It could hardly investigate in normal epithelial tissues, the same as in esophageal squamous cell carcinoma (ESCC) [ 21 ], since the two carcinomas were derived from squamous cells.…”

Section: Discussionmentioning

confidence: 99%

“…PABPC1 overexpression associated with BDNF-AS overexpression inhibited the proliferation, migration, and invasion of glioblastoma cells [ 18 ]. Simultaneously, the upregulation of PABPC1 promoted malignant progression in ovarian cancer [ 19 ], hepatocellular carcinoma [ 20 ], and esophageal squamous cell carcinoma (ESCC) [ 21 ]. Therefore, the role of PABPC1 in most cancers, especially squamous cell carcinoma, is to promote malignancy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy

Feng

et al. 2023

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background Nasopharyngeal carcinoma (NPC), especially the nonkeratinizing type, is a malignant tumor primarily occurring in southern China and Southeast Asia. Chemotherapy (CT) and combined radiotherapy (RT) is used to treat NPC. However, the mortality rate is high in recurrent and metastatic NPC. We developed a molecular marker, analyzed its correlation with clinical characteristics, and assessed the prognostic value among NPC patients with or without chemoradiotherapy. Methods A total of 157 NPC patients were included in this study, with 120 undergoing treatment and 37 without treatment. EBER1/2 expression was investigated using in situ hybridization (ISH). Expression of PABPC1, Ki-67, and p53 was detected with immunohistochemistry. The correlations of EBER1/2 and the expression of the three proteins having clinical features and prognosis were evaluated. Results The expression of PABPC1 was associated with age, recurrence, and treatment but not with gender, TNM classification, or the expression of Ki-67, p53, or EBER. High expression of PABPC1 was associated with poor overall survival (OS) and disease-free survival (DFS) and was an independent predictor depending on multivariate analysis. Comparatively, no significant correlation was observed between the expression of p53, Ki-67, and EBER and survival. In this study, 120 patients received treatments and revealed significantly better OS and DFS than the untreated 37 patients. PABPC1 high expression was an independent predictor of shorter OS in the treated (HR = 4.012 (1.238–13.522), 95% CI, p = 0.021) and the untreated groups (HR = 5.473 (1.051–28.508), 95% CI, p = 0.044). However, it was not an independent predictor of shorter DFS in either the treated or the untreated groups. No significant survival difference was observed between patients with docetaxel-based induction chemotherapy (IC) + concurrent chemoradiotherapy (CCRT) and those with paclitaxel-based IC + CCRT. However, when combined with treatment and PABPC1 expression, patients with paclitaxel-added chemoradiotherapy plus PABPC1 low expression had significantly better OS than those who underwent chemoradiotherapy (p = 0.036). Conclusions High expression of PABPC1 is associated with poorer OS and DFS among NPC patients. Patients with PABPC1 having low expression revealed good survival irrespective of the treatment received, indicating that PABPC1 could be a potential biomarker for triaging NPC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy

Feng

et al. 2023

BMC Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients with EC receiving neoadjuvant chemoradiation therapy, LNM is one of the crucial factors associated with overall survival 16. Regardless of the metastatic sites, LMN is an independent risk factor for poor prognosis in patients with ESCC 17-19. Therefore, in this study, we searched the dataset in TCGA database for DEGs in EC and the overlapped genes with LNM associated genes were identified.…”

Section: Discussionmentioning

confidence: 99%

“…16 Regardless of the metastatic sites, LMN is an independent risk factor for poor prognosis in patients with ESCC. [17][18][19] Therefore, in this study, we searched the dataset in TCGA database for DEGs in EC and the overlapped genes with LNM associated genes were identified. We finally localized three DEGs in EC that are associated with the LNM and relapse of EC, among which IGHV4-28 and IGLV6-57 are risk factors for EC initiation and progression, while KPRP might be a tumor suppressor in EC progression.…”

Section: Original Researchmentioning

confidence: 99%

Network analysis of genes associated with esophageal squamous cell carcinoma progression

Xia

2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

This study aims to identify possible genes associated with esophageal squamous cell carcinoma (ESCC) by bioinformatics tool and further explore the function of immunoglobulin heavy chain variable family 4 gene (IGHV4)-28 in the ESCC progression.The ESCC-related genes in Cancer Genome Atlas (TCGA) database were analyzed by bioinformatics tools, which finally identified IGHV4-28. The expression levels of IGHV4-28 in TE-4 and EC9706 cells were detected by quantitative reverse transcription-PCR (qRT-PCR). Then oe-IGHV4-28 or sh-IGHV4-28 was transfected into TE-4 and EC9706 cells to verify the effect on cell proliferation, migration, invasion, and apoptosis rate. In vivo, a nude mouse model of ESCC was developed, whereby the tumor volume and weight were calculated to evaluate the impact of IGHV4-8 on tumor growth.Bioinformatics analysis using TCGA database showed that IGHV4-28, IGLV6-57, and KPRP were all associated with ESCC progression. Kaplan-Meier (KM) analysis showed overexpression of IGHV4-28 is substantially associated with the survival rate of patients with ESCC. IGHV4-28 was highly expressed in TE-4 and EC9706 cell lines and overexpression of IGHV4-28 enhanced cell proliferation, invasion, and migration, as well as decreased apoptosis rate. Moreover, nude mice transplanted with IGHV4-28-silencing TE-4 cells showed restrained tumor weight and volume.In summary, IGHV4-28 was increasingly expressed in ESCC and may serve as a therapeutic target in the treatment of ESCC.

show abstract

“…Biomarkers are protein or protein fragment molecules produced by malignant cells that may be easily identified in a patient's blood or urine but not in the blood or urine of a healthy individual and play an important role in the diagnosis and prognosis of GBC [26][27][28]. Biomarkers are important in clinical trials, novel medicines, and adjuvant therapy modalities in oncology, and they also offer a prognosis estimate: Biomarkers have the potential to be employed in mass screening to detect asymptomatic people in the early stages of cancer.…”

Section: Cytopathological/ Histopathological Diagnosismentioning

confidence: 99%

Immune-Markers in GallBladder Lesions and their Clinico-Diagnostic and Prognostic Significance - An Overview

Agarwal¹,

AlRawaili²,

AlZalbani³

et al. 2023

Int J Pharm Res Allied Sci

View full text Add to dashboard Cite

Gallbladder benign diseases are common and usually cured without further consequences. Some benign illnesses increase the chance of cancer development significantly, whereas others resemble malignant disorders. The biomarkers discussed thus far are among the most extensively researched concerning the different diseases of GBC. Patients with gallbladder cancer are usually diagnosed in later stages when conventional treatments are ineffective. The lack of responsiveness of advanced instances of GBC to existing therapies necessitates the identification of novel prognostic and therapeutic approaches. Novel prognostic biomarkers may provide a crucial breakthrough in this area. Despite the available data and years of research, a prognostic marker that is 100% specific and sensitive to GBC is not yet available. A diverse number of molecular markers have been studied for their potential to be prognostic markers in GBC. p53 and HER2 have been studied very extensively and have shown promise. The deregulation and accumulation of the molecular markers we have discussed so far impact carcinogenesis of the gall bladder. Further analytical studies on the concentration levels of these markers in normal vs precancerous vs cancerous tissues should be carried out. Highly specific prognostic markers can help individualize treatment options to bring down the mortality rate in GBC.

show abstract

High-Expression of Cytoplasmic Poly (A) Binding Protein 1 (PABPC1) as a Prognostic Biomarker for Early-Stage Esophageal Squamous Cell Carcinoma

Cited by 8 publications

References 27 publications

Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy

Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy

Network analysis of genes associated with esophageal squamous cell carcinoma progression

Immune-Markers in GallBladder Lesions and their Clinico-Diagnostic and Prognostic Significance - An Overview

Contact Info

Product

Resources

About